WO2025254978 - DECOY RECEPTOR 3 (DCR3) BINDING PROTEINS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/254978
Publication Date
11.12.2025
International Application No.
PCT/US2025/031838
International Filing Date
31.05.2025
Title **
[English]
DECOY RECEPTOR 3 (DCR3) BINDING PROTEINS AND USES THEREOF
[French]
PROTÉINES DE LIAISON AU RÉCEPTEUR LEURRE 3 (DCR3) ET LEURS UTILISATIONS
Applicants **
WRENCH BIO, INC.
Inventors
ROZENFELD, Raphael
Priority Data
63/655,138
03.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5340 | |
| EPO | Filing, Examination, Granting | 102794 | |
| Japan | Filing, Examination, Granting | 4810 | |
| South Korea | Filing, Examination, Granting | 8127 | |
| USA | Filing, Examination, Granting | 32760 |
Total:
153,831
Contact Us
Abstract[English]
The present application discloses binding proteins that selectively bind to DcR3 and uses thereof in diagnostic and purification assays as well as therapeutic methods of treatment. Also described are fusion proteins which contain a first DcR3 binding protein that binds to DcR3 and inhibits binding of its ligands and a second DcR3 binding protein that binds to DcR3 but does not inhibit binding of its ligands. The binding proteins and fusion proteins can also be used in diagnostic and purification assays as well as therapeutic methods of treatment.[French]
La présente demande concerne des protéines de liaison qui se lient de manière sélective à DcR3 et leurs utilisations dans des dosages de diagnostic et de purification ainsi que des méthodes thérapeutiques de traitement. L'invention concerne également des protéines de fusion contenant une première protéine de liaison à DcR3 qui se lie à DcR3 et inhibe la liaison de ses ligands et une seconde protéine de liaison à DcR3 qui se lie à DcR3 mais n'inhibe pas la liaison de ses ligands. Les protéines de liaison et les protéines de fusion peuvent également être utilisées dans des dosages de diagnostic et de purification ainsi que des méthodes thérapeutiques de traitement.